Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Prepaid Assets (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Prepaid Assets for 5 consecutive years, with $8.4 million as the latest value for Q1 2026.

  • For Q1 2026, Prepaid Assets fell 35.39% year-over-year to $8.4 million; the TTM value through Mar 2026 reached $8.4 million, down 35.39%, while the annual FY2025 figure was $15.4 million, 26.42% down from the prior year.
  • Prepaid Assets hit $8.4 million in Q1 2026 for Phathom Pharmaceuticals, down from $15.4 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $20.9 million in Q4 2024 and bottomed at $975000.0 in Q3 2022.
  • Average Prepaid Assets over 5 years is $11.2 million, with a median of $12.9 million recorded in 2023.
  • Year-over-year, Prepaid Assets skyrocketed 1226.97% in 2023 and then plummeted 35.39% in 2026.
  • Phathom Pharmaceuticals' Prepaid Assets stood at $5.1 million in 2022, then surged by 157.34% to $13.2 million in 2023, then surged by 58.15% to $20.9 million in 2024, then fell by 26.42% to $15.4 million in 2025, then plummeted by 45.06% to $8.4 million in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $8.4 million, $15.4 million, and $13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.